| Oscar Insurance Guidelines | Allergy (Allergen) Immunotherapy | 2025-11-01 |
| Oscar Insurance Guidelines | limited to the Commercial Preferred Physician-Administered Specialty Drugs | 2025-11-01 |
| UHC Commercial Medical & Drug | Alpha1-Proteinase Inhibitors - Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Commercial Medical & Drug | Brineura® (Cerliponase Alfa) - Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Commercial Medical & Drug | Buprenorphine (Brixadi® & Sublocade®) - Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Commercial Medical & Drug | Hereditary Angioedema (HAE), Treatment and Prophylaxis - Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Commercial Medical & Drug | Ilaris® (Canakinumab) - Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Commercial Medical & Drug | Intracanalicular and Intravitreal Corticosteroid Implants - Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Commercial Medical & Drug | Krystexxa® (Pegloticase) - Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Commercial Medical & Drug | Leqvio® (Inclisiran) - Commercial Medical Benefit Drug Policy | 2025-11-01 |